In recent years muscarinic receptor agonists and cholinesterase inhibitors have been developed for the treatment of Alzheimer's disease. We have evaluated examples from both classes of compounds in rodent tests of reference and working memory, as well as tests that are sensitive to the side-effects of these compounds. Thus, three selective muscarinic receptor partial agonists L-689,660, (M1/M3), AF102B (M1/M3) and L-687,306 (M1) and two cholinesterase inhibitors, E2020 and eptastigmine, were ...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory.
If you are the owner of this record, you can report an update to it here: Report update to this record